GANX · Gain Therapeutics, Inc.
$1.82
+0.05 (+2.82%)
At close · Aug 31
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report.”View the 10-Q filed Aug 11, 2026
Market Cap
$77.25M
Shares
43.64M
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-06-12 | H.C. Wainwright Fireside Chat with President and CEO Gene Mack | Event |
| 2026-03-23 | ROTH Fireside Chat with President and CEO Gene Mack | Event |
| 2026-02-25 | Oppenheimer Fireside Chat with President and CEO Gene Mack – 36th Annual Healthcare Life Sciences Conference | Conference |
| 2026-01-06 | Parkinson’s Disease KOL Event: Understanding GCase Substrates in Parkinson’s Disease – Perspectives on Biomarkers and Disease Modification | Event |
| 2025-10-13 | Parkinson’s Disease KOL Event: Biomarkers, Clinical Endpoints, and the Path to Disease Modification | Event |
| 2025-05-21 | Citizens Life Sciences Conference Company Presentation | Conference |
Key facts
CIK
1819411
CUSIP
36269B105
13F (30d)
42 filings
42 filers
Visit website
Investor relations